gastrointestinal News
-
Study results presented at AGW show Atmo Gas Capsule can be used to assess regional gastrointestinal transit in healthy adults
A Monash University comparative study has found Atmo Biosciences’ novel ingestible gas-sensing capsule to be similar to a validated wireless motility capsule (WMC) when assessing regional gastrointestinal transit time in healthy adults. Findings from the study, led by Professor Peter Gibson, are being presented in a poster at Australian Gastroenterology Week (AGW), being held virtually ...
-
Atmo featured on Medical Director’s Healthtech Showcase
Atmo Biosciences CEO Mal Hebblewhite was invited to present at Medical Director’s Healthtech Showcase. In the video below, Mal gives an overview of Atmo Biosciences then talks to showcase host Dominique Powis about Atmo’s journey so far, and how its ingestible gas-sensing capsule can improve diagnosis and treatment for common gastrointestinal disorders. ...
-
Microbiologists’ work adds to research on microbiome fungi and childhood disease
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. Much of the research has focused on gut bacteria and viruses, leaving a third factor - fungi - little studied. An international consortium of scientists has conducted the first large-scale ...
-
Huateng Pharma Launches Exciting New Product Line - Fexuprazan and Vonoprazan Intermediates
Huateng Pharma, a leading innovator in pharmaceutical intermediates, is proud to announce the introduction of its latest product line - Gastrointestinal API Intermediates, featuring the groundbreaking compounds Fexuprazan and Vonoprazan Intermediates. These cutting-edge substances have been meticulously developed to meet the growing demands of the pharmaceutical industry. Fexuprazan Intermediates ...
-
Showcase
Atmo Biosciences awarded Australian Government grant to automate and scale-up manufacturing of ingestible gas-sensing capsule
Atmo Biosciences has been awarded an Australian Government Manufacturing Modernisation Fund (MMF) grant to support manufacturing automation and scale-up for the Atmo Gas-Sensing Capsule. The Round 2 MMF grants, part of the Government’s Modern Manufacturing Strategy, are for small-medium sized businesses to transform manufacturing and to support job growth and develop a more skilled ...
-
Palisade Bio Announces Inducement Awards Under Inducement Plan For Key New Hires
Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan. On May 4, 2022, the Company’s Compensation Committee granted options to four new non-executive employees covering an aggregate of 140,000 shares ...
By Palisade Bio
-
Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR Targets for Drug Discovery
Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and New York City-based Kallyope, pioneers in drug discovery involving the gut-brain axis, have entered a strategic research collaboration to identify and validate novel G protein-coupled receptor (GPCR) targets with a goal of creating new drug discovery programs in the area of ...
-
Results from Orviglance comparison study to gadolinium accepted for oral presentation at the ESGAR confere
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the study where Orviglance was compared against a gadolinium-based contrast agent has been accepted as an oral scientific presentation at the ESGAR conference to be held in May 31 – June 3 in Lisbon, Portugal. “We are very pleased that the study has been selected as an oral scientific presentation at the prestigious ...
-
Palisade Bio To Present At The H.C. Wainwright BIOCONNECT Virtual Conference And Biotech Showcase
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor ...
By Palisade Bio
-
Onlume Receives FDA 510(k) Clearance for Fluorescence-guided Surgery Device
OnLume has received 510(k) clearance from the U.S. Food & Drug Administration (“FDA”) to market its first product, a fluorescence guided surgery (FGS) system. The OnLume Imaging System is indicated for fluorescence imaging of blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, reconstructive, and micro surgeries. This ...
By OnLume Inc.
-
Posters Presented at DDW 2022 Demonstrate G-Tech System Motility Measurements Correlate with Antroduodenal Manometry Measurements and Can be Used to Characterize Colon Motility Alteration
MOUNTAIN VIEW, Calif., May 26, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced that two posters were presented at Digestive Disease Week Conference held in San Diego in from May 21 through May 24. The first poster, entitled Wireless non-invasive patches detect phase III of the migrating motor complex in ...
-
EsoCap featured in the Medicine Maker
“We are extremely pleased that The Medicine Maker is reporting on how EsoCap’s unique and innovative topical drug delivery system offers new treatment options for diseases of the esophagus,” said Isabelle Racamier, EsoCap AG CEO. “The interview is a great opportunity to highlight the challenges of esophageal disease and how EsoCap is innovating localized esophagus ...
By EsoCap AG
-
G-Tech Medical Receives FDA Clearance for its Gastrointestinal Motility Monitoring System
MOUNTAIN VIEW, Calif., January 13, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Wireless Patch System (WPS) for non-invasive myoelectric activity measurement. The G-Tech WPS is a tool that provides gastric and intestinal myoelectrical ...
-
Esocap Featured In Fierce Pharma
“We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and the current Phase II program, as well as further use of its platform in additional indications,” said Isabelle Racamier, EsoCap AG CEO. “This strengthens our resolve to bring a major improvement to the lives of patients using ...
By EsoCap AG
-
New Research Shows Progression to Esophageal Cancer as Detected by WATS3D
A newly published study as lead article in Gastrointestinal Endoscopy shows that Barrett’s esophagus (BE) and dysplasia progress to esophageal cancer at similar, or even higher, rates when diagnosed by WATS3D (wide-area transepithelial sampling with three-dimensional analysis) as they do when diagnosed by conventional forceps biopsies. This study titled “Progression of ...
-
Suono Bio, Inc. Announces Formulation-Agnostic Platform for the Delivery of RNA Therapeutics
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery ...
By Suono Bio
-
Palisade Bio (Nasdaq: PALI) To Participate In The Virtual Investor Management And KOL Roundtable Event
- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET. Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief ...
By Palisade Bio
-
Palisade Bio (Nasdaq: PALI) To Participate In The 2022 Virtual Growth Conference Presented By Maxim Group And Hosted By M-Vest
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that of Palisade Bio, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28–30, 2022. As part of the conference, a video webcast of the ...
By Palisade Bio
-
Atmo Biosciences secures $9.6 million in oversubscribed capital raise
Atmo Biosciences has closed a successful, oversubscribed A$9.6m capital raise. The raise was led by two new, cornerstone investors – Sydney-based investment firm Alium Capital Management and Japanese multinational company Otsuka Pharmaceutical. The funding will enable Atmo to accelerate product development of its gas-sensing capsule, which detects clinically important gaseous biomarkers ...
-
Atlantic Healthcare plc acquires global rights to renzapride for the treatment of gastrointestinal motility disorders
Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases, today announced that the Company has entered into an agreement to acquire the global rights to renzapride from EndoLogic LLC (“EndoLogic”). Renzapride is a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you